EP2819517A2 - Petite moléculs présentant des propriétés antivirales - Google Patents

Petite moléculs présentant des propriétés antivirales

Info

Publication number
EP2819517A2
EP2819517A2 EP12868920.5A EP12868920A EP2819517A2 EP 2819517 A2 EP2819517 A2 EP 2819517A2 EP 12868920 A EP12868920 A EP 12868920A EP 2819517 A2 EP2819517 A2 EP 2819517A2
Authority
EP
European Patent Office
Prior art keywords
virus
small molecule
cells
monolayer
antiviral properties
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12868920.5A
Other languages
German (de)
English (en)
Inventor
Oleg Nikolayevich CHUPAKHIN
Oleg Ivanovich KISILEV
Vladimir Leonidovich RUSINOV
Valery Nikolaevich CHARUSHIN
Nina Pablovna TUGOVA
Natliya Roseyvna MEDVEDERA
Evgeny Hartsisovich ULOMSKII
David Mark Evans
Ella Germanovna DYEVA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GRL
Original Assignee
GRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GRL filed Critical GRL
Publication of EP2819517A2 publication Critical patent/EP2819517A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Definitions

  • the invention reiates to biologically active compounds possessing antiviral properties for the treatment and prevention of viral infections of animals and humans.
  • the invention can be used in hospitals, research laboratories, as well as livestock and poultry.
  • the closest in structure to the claimed compound from this series (1 ) can be regarded as a prototype.
  • the compound (1 ) in a concentration of 40 ug / mi in in vitro experiments the infectious titer of influenza ⁇ / ⁇ 3 ⁇ 2 and influenza virus
  • CC50 concentration at which 50% of the cells die
  • the invention is the small molecule (2) which has antiviral activity.
  • the small molecule (2) has demonstrated low toxicity.
  • Fig. 1 shows a scaffold for a small molecule.
  • Fig. 2 shows a small molecule based on the scaffold of Fig. 1 .
  • the compound produced from this synthesis is a pale yellow crystaliine solid, soluble in water, methanol, dimethyl sulfoxide, insoluble in benzene, ether and most other solvents.
  • the compound is orally ingestibie and show efficacy against viruses including the influenza virus.
  • Viruses Used a one-day monolayer culture of epithelial cells MDCK (dog kidney) Viruses. To assess the antiviral activity of the virus used the reference A / Puerto Rico/8/34, as well as pandemic influenza virus H1 1 v A/San kt-Peterburg/2/09 (similar to the so-called virus "swine fiu» A/Caiifornia/7/09).
  • the maximum tolerable concentrations of the compounds was determined by MTT test in ceil culture MDCK.
  • Testing of toxicity was carried out as follows: weighed weigh weighing 5 mg in a sterile test tube 5 ml. and the diluted growth medium for the cells MDCK (a-MEM, Bioiot, St. Russia) to a concentration of 1 mg / mL, thus obtaining a basic solution. More of the same medium made eight consecutive binary dilutions (500, 250, 125, 82.5, 31 .25, 1 5.13, 7.56 and 3.78 mg / mi, respectively), which was used for toxicity testing. The experience set in the four parallels for each concentration. One-day cell culture MDCK, grown in 98 ⁇ vveli plates (Costar), checked visually in an inverted microscope on the integrity of the monolayer.
  • the plates were washed twice with medium without serum, and then have made the test compound in appropriate concentrations in a volume of 100 ml in each well.
  • the plates were incubated for 72 h at 37 ° C in the presence of 5% C02, and then recorded the results of the experiment visually assessing the integrity of the monolayer compared with control cells, and by the MTT (quantitatively evaluating the viability of the ceils) using the tablet reader Hydex Chameleon.
  • Statistical analysis was performed using the program Statistica 6.0.
  • the plates were incubated for 60 min at 37 ° C in the presence of 5% CO 2, and then washed with medium to remove unbound viral particles to cells. Continue to make the drug in the wells with virus dilutions in 100 mi of the appropriate concentration. Each concentration of test compound was placed in four parallels for each virus dilution. Control wells filled with growth medium in the same volume. Also, the wells were left to re-test toxicity used concentrations.
  • the plates were incubated for 72 h at 37 0 G, and then recorded the results of the experiment visually assessing the integrity of the monolayer as compared to control ceils and the degree of cytopathic effect of virus in ceil culture, put hemagglutination reaction and MTT method was used to quantify cell viability using the tablet reader Hydex Chameleon.
  • Evaluation of toxicity, as well as evaluation of the antiviral action of drugs produced by three methods 1 ) monitoring and evaluation of the integrity of the monolayer cells under an inverted microscope. Implies a comparison of cell morphology of control wells with experienced and registration of changes under the influence of an agent (drug, virus, etc.). The change of morphology could include violating the integrity of the monolayer, changes in cell shape, expression of cytopathic effect in virus infection.
  • MTT The method used in the evaluation of drug sensitivity, based on the ability of dehydrogenases of living cells to restore the form of colorless 3- 4,5-dimethylthiazol-2-yl-2 ,5-difenilterarazola (MTT reagent) to blue crystalline farmazana soluble in DMSO or 96% alcohol. Saturation of color indicates the intensity of metabolic processes in cells, ie, the normal level of viability. The color intensity is recorded with a spectrophotometer and the absorbance values obtained can be used for statistical data processing.
  • the concentration of the drug during that kills 50% of a monolayer of cells in a test on the MDCK cells was 177 pg / ml.
  • Drug concentration at which all the cells survive the monolayer was 62.5 micrograms / ml, which was used to test the antiviral activity of the drug.
  • connection (2) in much smaller concentrations, in comparison with toxic, has a pronounced antiviral activity, reducing the titers of virus A / Puerto Rico/8/34 virus and pandemic influenza HlNlv A/Sankt- Peterburg/2/09 (A/California/7/09-podobny) for 3,0 lg concentrations 62.5 and 125 ug / ml, respectively, then there is a more active antiviral compound than with a prototype.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Cette invention concerne un nouveau squelette d'une petite molécule présentant des propriétés antivirales, molécule aux propriétés antivirales dont la faible toxicité a été mise en évidence.
EP12868920.5A 2012-02-14 2012-02-14 Petite moléculs présentant des propriétés antivirales Withdrawn EP2819517A2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2012/025070 WO2013122575A2 (fr) 2012-02-14 2012-02-14 Petite moléculs présentant des propriétés antivirales

Publications (1)

Publication Number Publication Date
EP2819517A2 true EP2819517A2 (fr) 2015-01-07

Family

ID=48984871

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12868920.5A Withdrawn EP2819517A2 (fr) 2012-02-14 2012-02-14 Petite moléculs présentant des propriétés antivirales

Country Status (3)

Country Link
EP (1) EP2819517A2 (fr)
JP (1) JP2015507007A (fr)
WO (1) WO2013122575A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015016818A1 (fr) * 2013-07-29 2015-02-05 Ghias Asghar Nouvel agent thérapeutique oral antiviral dérivé d'azolo-1,2,4-triazine
US20190211024A1 (en) * 2016-08-19 2019-07-11 General Research Laboratory Small molecules having antiviral properties

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4405619A (en) * 1981-09-02 1983-09-20 Diamond Shamrock Corporation Antiinflammatory substituted-1,2,4-triazolo[4,3-b]-1,2,4-triazines
CL2003002353A1 (es) * 2002-11-15 2005-02-04 Vertex Pharma Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic
US20090156602A1 (en) * 2004-11-24 2009-06-18 Nigel Graham Cooke Organic Compounds
RU2294936C1 (ru) * 2005-06-29 2007-03-10 Государственное Образовательное Учреждение Высшего Профессионального Образования Уральский Государственный Технический Университет-УПИ Натриевая соль 2-метилтио-6-нитро-1,2-4-триазоло[5,1-c]-1,2,4-триазин-7(4h)-она, дигидрат, обладающая противовирусной активностью
MX2009005174A (es) * 2006-11-23 2009-05-25 Novartis Ag Derivados de 5-sulfanilmetil-[1,2,4]triazol[1,5-a]pirimidin-7-ol como antagonistas de cxcr2.
RU2343154C2 (ru) * 2007-01-31 2009-01-10 Общество с ограниченной ответственностью Научно-техническое предприятие "Лиганд" СПОСОБ ПОЛУЧЕНИЯ НАТРИЕВОЙ СОЛИ 2-МЕТИЛТИО-6-НИТРО-1,2,4-ТРИАЗОЛО[5,1-c]-1,2,4-ТРИАЗИН-7-ОНА, ДИГИДРАТА
RU2345080C2 (ru) * 2007-02-16 2009-01-27 ГОУ ВПО Уральский государственный технический университет-УПИ 4-(4'-ГИДРОКСИБУТИЛ)-6-ФЕНИЛ-1,2,4-ТРИАЗОЛО[5,1-c][1,2,4]ТРИАЗИН-7-ОН
RU2376307C1 (ru) * 2008-05-27 2009-12-20 Институт органического синтеза им. И.Я. Постовского Уральского отделения Российской академии наук 4-((Z)-4'-ГИДРОКСИБУТЕН-2'-ИЛ)-2-R-6-ФЕНИЛ-1,2,4-ТРИАЗОЛО[5,1-c][1,2,4]ТРИАЗИН-7-ОНЫ

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2013122575A3 *

Also Published As

Publication number Publication date
WO2013122575A2 (fr) 2013-08-22
WO2013122575A3 (fr) 2014-05-01
JP2015507007A (ja) 2015-03-05

Similar Documents

Publication Publication Date Title
Ter Ellen et al. Resveratrol and pterostilbene inhibit SARS-CoV-2 replication in air–liquid interface cultured human primary bronchial epithelial cells
Ma et al. Oral exposure of Kunming mice to diisononyl phthalate induces hepatic and renal tissue injury through the accumulation of ROS. Protective effect of melatonin
Webster et al. H5N1 outbreaks and enzootic influenza
Nie et al. Antiviral activity of Isatidis Radix derived glucosinolate isomers and their breakdown products against influenza A in vitro/ovo and mechanism of action
Zhang et al. An eco-and user-friendly herbicide
Sirakanyan et al. A new microtubule-stabilizing agent shows potent antiviral effects against African swine fever virus with no cytotoxicity
Qaswal et al. The potential role of lithium as an antiviral agent against SARS-CoV-2 via membrane depolarization: Review and hypothesis
WO2013122575A2 (fr) Petite moléculs présentant des propriétés antivirales
Broni et al. Cheminformatics-based study identifies potential ebola VP40 inhibitors
Cui et al. 1, 4-Naphthoquinone-coated black carbon, a kind of atmospheric fine particulate matter, affects macrophage fate: new insights into crosstalk between necroptosis and macrophage extracellular traps
Zhang et al. Ethanol extract of Caesalpinia decapetala inhibits influenza virus infection in vitro and in vivo
Li et al. A physiologically based in silico tool to assess the risk of drug-related crystalluria
Bastos et al. A novel insight on SARS-CoV-2 S-derived fragments in the control of the host immunity
Justice et al. Quantitative proteomic analysis of enriched nuclear fractions from BK polyomavirus-infected primary renal proximal tubule epithelial cells
RU2455304C1 (ru) 6-(2'-АМИНО-2'-КАРБОКСИЭТИЛТИО)-2-МЕТИЛТИО-4-ПИВАЛОИЛОКСИМЕТИЛ-1,2,4-ТРИАЗОЛО[5,1-c]1,2,4-ТРИАЗИН-7(4Н)-ОН
CN105287539A (zh) 延胡索甲素的新应用
Lingwan et al. Antiviral phytochemicals identified in Rhododendron arboreum petals exhibited strong binding to SARS-CoV-2 MPro and Human ACE2 receptor
Swaroop et al. Discovery of immunomodulators from plant kingdom targeting IL-6 for the effective management therapy of SARS-CoV-2.
Zambrano-Estrada et al. Evaluation of the antiviral effect of chlorine dioxide (ClO2) using a vertebrate model inoculated with avian coronavirus
Wikan et al. Alpinetin Suppresses Zika Virus-Induced Interleukin-1β Production and Secretion in Human Macrophages
Boff et al. Semisynthetic cardenolides acting as antiviral inhibitors of influenza A virus replication by preventing polymerase complex formation
Gridina et al. The effect of the structure of derivatives of nitrogen-containing heterocycles on their anti-influenza activity
RU2641380C1 (ru) Способ моделирования интоксикации бериллием
CN111603526A (zh) 一种复方银花解毒药物在制备抗病毒药物中的应用
US20240307434A1 (en) Use of lutetium salt compounds for antiviral effect

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140912

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150901